Assessment Of The Quality Of Life and Health Resource Utilization Burden Among Patients With Primary Immunodeficiency Disorder (PIDD) Prior To Treatment

PIDD patients often suffer from multiple infections and functional impairment prior to initiation of immunoglobulin (Ig) treatment, which may negatively impact their health related quality of life (HRQOL) and result in high health resource utilization (HRU). This analysis focused on assessing the potential HRQOL and HRU burden among PIDD patients before Ig therapy. This was a prospective, observational study of newly diagnosed PIDD patients requiring Ig therapy. Eligible patients were recruited from the US, UK, and Brazil. Patients’ HRQOL was assessed at baseline prior to first infusion, using the SF-36 for adults and the Pediatric Quality of Life Inventory (PedsQL) for children. Hospitalizations, ER visits, and antibiotic use 6 months prior to enrollment were also collected. A total of 30 patients have enrolled in the study to date (20 adults, 10 children). The mean baseline SF-36 Physical Component Score (35.82 vs. 50.0, p<0.0001) and Mental Component Score (38.17 vs. 50.0, p=0.0134) were significantly lower among the adult PIDD patients compared to the US general population norms. Among children, the mean baseline PedsQL Total Score was also significantly lower than the US general population (68.87 vs. 83.84, p=0.0008). The mean rates of hospitalizations, ER visits and antibiotic prescriptions per person in the past 6 months were 1.6, 2.4, and 4.4, respectively. Results suggest PIDD patients prior to treatment have diminished HRQOL compared to the US general population and high rates of health service utilization, highlighting the significant HRQOL and HRU burden among these patients.